DSCAM-AS1 up-regulation in invasive ductal carcinoma of breast and assessment of its potential as a diagnostic biomarker

Article type: Research Article

Authors: Khorshidi, Hamidreza^a | Azari, Iman^b | Oskooei, Vahid Kholghi^b | Taheri, Mohammad^b | Ghafouri-Fard, Soudeh^b;

Affiliations: [a] Department of Surgery, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran | [b] Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence: [*] Corresponding author: Soudeh Ghafouri-Fard. E-mail: s.ghafourifard@sbmu.ac.ir

Abstract: BACKGROUND:The long non-coding RNA (lncRNA) DSCAM-AS1 has been demonstrated to participate in the pathogenesis of breast cancer and tamoxifen resistance. OBJECTIVE:To evaluate expression profile of DSCAM-AS1 in invasive ductal carcinoma of breast and its suitability as a biomarker for diagnosis of breast cancer. METHODS:We evaluated expression of DSCAM-AS1 in 108 breast tissues including tumoral and adjacent non-cancerous tissues (ANCTs) by means of quantitative real time PCR. RESULTS:DSCAM-AS1 was up-regulated in tumoral tissues compared with ANCTs (Fold change = 2.86, P = 0.011). Its expression was significantly higher in patients aged less than 55 compared with older patients (P = 0.02). However, its expression levels had not a good performance as a diagnostic biomarker for breast cancer. CONCLUSIONS:The significant up-regulation of DSCAM-AS1 in tumoral tissues compared with ANCTs provides further evidences for participation of this lncRNA in the pathogenesis of breast cancer.

Keywords: DSCAM-AS1, breast cancer

DOI: 10.3233/BD-180351

Journal: Breast Disease, vol. 38, no. 1, pp. 25-30, 2019